Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model by Joseph C. McCarthy, MS, Mark Aronovitz, MS, Jennifer J. DuPont, PhD, Timothy D. Calamaras, PhD, Iris Z. Jaffe, MD, PhD, Robert M. Blanton, MD

Get full text